Table 1 Characteristics of the prostate cancer molecular subtypes.
From: Prostate epithelial genes define therapy-relevant prostate cancer molecular subtype
Molecular subtype | Luminal A | Luminal S | AVPC-I | AVPC-M |
|---|---|---|---|---|
Consensus cluster (Prevalencea) | A (30.0%) | B (26.0%) | C (14.7%) | D (4.2%) |
Transcriptomic characteristics | Luminal-like adipogenic | Luminal-like secretory | Immune, angiogenic cell cycle-active | Myc-active DNA-repairing |
Genomic characteristics | ETS fusion (−) SPOP-mut (+) Chr6q del (+) | ETS fusion (+) PTEN del (+) TP53 mut/del (−) | ETS fusion (+) PTEN del (+) TP53 mut/del (+) PIK3CA mut (−) | ETS fusion (+) PTEN del (+) TP53 mut/del (+) PIK3CA mut (+) |
AVPC-msa | 3% | 11% | 24% | 23% |
Serum PSA/PAP ratio (predicted) | High | Low | Intermediate | High |
Docetaxel response | Resistant | Sensitive | Sensitive | Resistant |
AR inhibitor response | Sensitive | Sensitive | Resistant | Resistant |
Potential therapy | AR inhibitors | AR inhibitors +Taxanes | Taxanes +Immunotherapy | DNA-damaging agents (Platinum, Purine analogues) |
